Evercore ISI analyst Joshua Schimmer maintained a Buy rating on PMV Pharmaceuticals (PMVP – Research Report) yesterday and set a price target of $50.00. The company’s shares closed last Monday at $16.99, close to its 52-week low of $14.42.
According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 6.6% and a 46.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
Currently, the analyst consensus on PMV Pharmaceuticals is a Strong Buy with an average price target of $49.75, which is a 210.5% upside from current levels. In a report issued on March 2, Oppenheimer also upgraded the stock to Buy with a $30.00 price target.
See the top stocks recommended by analysts >>
Based on PMV Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.01 million. In comparison, last year the company had a GAAP net loss of $10.45 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Read More on PMVP:
- Evercore ISI Thinks Rocket Pharmaceuticals’ Stock is Going to Recover
- Evercore ISI Thinks Restaurant Brands International’s Stock is Going to Recover
- Evercore ISI Thinks Goldman Sachs Group’s Stock is Going to Recover
- Evercore ISI Thinks Monster Beverage’s Stock is Going to Recover
- Evercore ISI Maintains Their Hold Rating on Keurig Dr Pepper (KDP)
